Biomea Fusion completes enrolment in COVALENT-211 icovamenib trial
Biomea Fusion has completed enrolment in COVALENT-211, its randomised, double-blind, placebo-controlled Phase II trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (T2D) who remain inadequately controlled on standard-of-care antihyperglycaemic therapies. The San Carlos, California-based company said it enrolled 64 participants across 18 clinical sites, randomised 2:1 to receive either icovamenib 100 mg once daily or placebo for 12 weeks, followed by a 40-week off-treatment period. Topline results for the Week 26 primary endpoint are anticipated in the first quarter of 2027.
Icovamenib is an orally administered small molecule that targets menin, a transcriptional regulator implicated in beta-cell biology. Preclinical data suggest the compound promotes beta-cell proliferation and enhances insulin production. COVALENT-211 builds on findings from the earlier Phase II COVALENT-111 trial, in which a 12-week course of icovamenib produced a placebo-adjusted mean HbA1c reduction of up to 1.5% in severe insulin-deficient patients, with the effect persisting to Week 52 and accompanied by increased C-peptide levels measured off treatment.
Two distinct patient populations
Biomea is pursuing two complementary Phase II programmes targeting clinically distinct T2D subgroups. COVALENT-212, evaluating icovamenib in patients who are not achieving glycaemic targets despite GLP-1-based therapy, remains ongoing and is expected to complete enrolment before the end of the year, with 26-week topline data anticipated in the second quarter of 2027. The decision to target GLP-1 non-responders is strategically significant: clinical research cited in the release estimates that 20 to 40 per cent of T2D patients on GLP-1 receptor agonist-based regimens fail to achieve adequate glucose control and subsequently progress to insulin-based treatment.
Interim chief executive Mick Hitchcock said the programme was progressing in line with the company's development strategy and that the durability of glycaemic improvements seen in earlier work provided the clinical rationale for both trials.
Market context and competitive positioning
The menin inhibitor space in diabetes is early-stage and largely distinct from the oncology menin inhibitor programmes, where revumenib and ziftomenib have drawn regulatory and commercial attention. Biomea is among a small number of companies investigating menin as a beta-cell restorative target rather than a cancer target, and the approach carries meaningful differentiation from the dominant GLP-1 receptor agonist category. However, the durability hypothesis remains to be confirmed in adequately powered controlled trials: COVALENT-111 was a Phase II signal-finding study, and the placebo-adjusted HbA1c reductions, while directionally encouraging, were drawn from relatively small subgroup analyses.
The broader T2D treatment landscape remains highly competitive. The GLP-1 receptor agonist class, led by semaglutide and tirzepatide, has reshaped prescribing patterns and raised the bar for novel agents entering the space. A beta-cell restorative mechanism, if validated in larger trials, could address a fundamentally different axis of the disease and serve populations poorly served by weight-centric approaches, particularly lean, insulin-deficient patients with low BMI who fall outside the typical GLP-1 responder profile.
Biomea will also need to demonstrate a clean safety profile across longer observation windows. The COVALENT-111 52-week data showed no treatment-related serious adverse events or discontinuations, which is an encouraging signal, but the COVALENT-211 and COVALENT-212 datasets will be the first adequately powered tests of that safety picture in more tightly defined patient populations.
The company plans to report sequentially from both Phase II trials through the first half of 2027, giving investors and the clinical community a clearer read on whether icovamenib can establish a differentiated position in a crowded metabolic disease market.